Drug profile · INN
levamisole hydrochloride
ERGAMISOL
levamisole hydrochloride (ERGAMISOL) is a nicotinic acetylcholine receptor alpha subunit agonist. Route of administration: oral. Current US regulatory status: approved.
Drug details — levamisole hydrochloride
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 1
- Data quality
- 0.84
Quick answer
levamisole hydrochloride (ERGAMISOL) is a nicotinic acetylcholine receptor alpha subunit agonist. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Nicotinic acetylcholine receptor alpha subunit agonist
Primary target: Nicotinic acetylcholine receptor alpha subunit
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Frequently asked questions
What is levamisole hydrochloride?
levamisole hydrochloride (ERGAMISOL) is a nicotinic acetylcholine receptor alpha subunit agonist. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for levamisole hydrochloride?
ERGAMISOL is a marketed brand name for levamisole hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of levamisole hydrochloride?
levamisole hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.